PK Profile

Hit invasive candidiasis hard and early with high plasma drug concentrations1

REZZAYO® has a familiar echinocandin mechanism of action with a long half-life that allows for once-weekly IV dosing1,2

The first dose of REZZAYO® is 2x greater than subsequent doses — or front-loaded — to yield high plasma drug concentrations early in therapy and give lasting fungicidal coverage1,3

Early, lasting high plasma drug concentrations4

Review efficacy of once-weekly REZZAYO®

See the Data

INDICATIONS AND USAGE

REZZAYO® is an echinocandin antifungal indicated in adults and pediatric patients 12 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data.

Limitations of Use

REZZAYO® has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida.

IMPORTANT SAFETY INFORMATION

Contraindications

REZZAYO® is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.

Warnings and Precautions

  • Hypersensitivity Reactions, including Anaphylaxis: Cases of serious hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving REZZAYO®. If these reactions occur, discontinue REZZAYO® and administer appropriate treatment.
  • Infusion-related Reactions: REZZAYO® may cause infusion-related reactions, including flushing, sensation of warmth, urticaria, nausea, or chest tightness. If these reactions occur, slow or pause the infusion.
  • Photosensitivity: REZZAYO® may cause photosensitivity. Advise patients to use protection from sun exposure and other sources of UV radiation.
  • Hepatic Adverse Reactions: Abnormalities in liver tests have been seen in clinical trial patients treated with REZZAYO®. Monitor patients who develop abnormal liver tests and evaluate patients for their risk/benefit of continuing REZZAYO® therapy.

Adverse Reactions

Most common adverse reactions (incidence ≥ 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia.

Please see full Prescribing Information.

Important Safety Information  

INDICATIONS AND USAGE

REZZAYO® is an echinocandin antifungal indicated in adults and pediatric patients 12 years of age or older who have limited or no alternative options for the

Contraindications

REZZAYO® is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.

References:1. REZZAYO®. Prescribing information. Melinta Therapeutics, LLC; 2025. 2. Thompson GR 3rd, Soriano A, Cornely OA, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023;401(10370):49-59. doi:10.1016/S0140-6736(22)02324-8 3. Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis. 2021;73(11):e3647-e3655. doi:10.1093/cid/ciaa1380 4. Melinta Therapeutics. Data on file. 2023.